Section 4: Vaccine Safety Public Health and Clinical ...

A Merck postmarketing study is underway to assess risk of febrile seizures 5–12 days after MMRV vaccine; interim results were consistent with the VSD study findings but were not statistically significant (CDC MMWR, 2008). Limited data are available on the risk of febrile seizures after the second dose of MMRV vaccine. ................
................